Peanut INT301

Protecting those who suffer from peanut allergy

nut allergy desensitization
new peanut allergy treatment
food allergy desensitization therapy

Peanut allergy is a life-threatening disease with only one approved medical treatment option, which may not be suitable for some peanut allergy sufferers due to side effects and potential safety issues. Avoidance of peanut consumption is typically practiced by affected individuals, coupled with reliance on antihistamines or epinephrine injection in the event of symptoms triggered by accidental exposure. Strict dietary avoidance is often expensive and hard to achieve and accidental exposure to peanut allergens is common.

INT301 is the initial product in development by Intrommune specifically designed to help those who suffer from peanut allergy. The product is intended to significantly raise a patient’s immune threshold through daily use of OMIT toothpaste beyond what has triggered a potentially dangerous allergic reaction via accidental exposure. This additional protection helps relieve the persistent anxiety of peanut allergic individuals toward accidental exposure.

Intrommune

Peanut INT301: OMEGA Clinical Trial

Intrommune’s Phase 1 OMEGA Clinical Trial was a 48-week, double-blind, placebo-controlled trial involving 32 adult patients with peanut allergy to assess the safety of INT301. Please visit our News & Resources page to stay up-to-date on our progress and be the first to know when we embark on Phase 2.

Slide 1 Heading
Lorem ipsum dolor sit amet consectetur adipiscing elit dolor
Click Here
Slide 2 Heading
Lorem ipsum dolor sit amet consectetur adipiscing elit dolor
Click Here
Slide 3 Heading
Lorem ipsum dolor sit amet consectetur adipiscing elit dolor
Click Here
Previous slide
Next slide
Intrommune toothpaste delivers allergen protein
Toothpaste slurry coats the mouth so more allergen protein can bind with cells on the surface of the oral mucosal epithelium. The opposing charges of the protein and surface cells attracts them to each other to form a strong bond.
Langerhans Cells process and display allergen proteins
Oral Langerhans cells capture allergen protein as it diffuses into the oral mucosa, displaying key identifiers on their surface before travelling to regional lymph nodes.  
Langerhan cells trigger the re-education of the immune system
Once in the regional lymph nodes Langerhans cells activate naive T cells causing them to differentiate into either T regulatory (Treg) cells or T helper type 1 (Th1) cells.
Differentiated T Cells decrease the allergic response
Treg and Th cells travel through lymph vessels and distribute themselves throughout the mucosa of the aerodigestive tract where they decrease the allergic immune response the next time there is exposure to the specific allergen protein. 
Previous slide
Next slide